BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

Trial Profile

BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Golimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BioTRAC
  • Sponsors Janssen Inc; Merck & Co
  • Most Recent Events

    • 17 Jun 2017 Results (n=188) assessing validation of new potential targets for remission in psoriatic arthritis presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results assesseng incidence of disease worsening in nkylosing spondylitis and rheumatoid arthritis patients on long-term therapy (n= 621) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 13 Jun 2017 Planned End Date changed from 31 Dec 2020 to 17 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top